Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Matsuse, Michiko ^a   Sasaki, Kensaku ^a   Nishihara, Eijun ^b   Minami, Shigeki ^a   Hayashida, Chisa ^a   Kondo, Hisayoshi ^a   Suzuki, Keiji ^a   Saenko, Vladimir ^a   Yoshiura, Koh ichiro ^a   Mitsutake, Norisato ^a,c   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KUMA HOSPITAL   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAF GENE; CARCINOGENESIS; CHROMOSOME 22; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER ALTERATION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; JAPANESE; KARYOTYPE; MALE; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; PTC1 GENE; PTC3 GENE; RET GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID PAPILLARY CARCINOMA; UNIPARENTAL DISOMY; ADOLESCENT; ASIAN; CLASSIFICATION; COPY NUMBER VARIATION; GENETIC ASSOCIATION; GENETICS; HUMAN GENOME; JAPAN; MIDDLE AGED; MUTATION; PATHOLOGY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION; THYROID NEOPLASMS; UNIPARENTAL DISOMY; YOUNG ADULT;

EID: 84860470964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036063     Document Type: Article

References (47)

1. Xing M, (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762.
2. Kondo T, Ezzat S, Asa SL, (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306.
3. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, et al. (2004) Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23: 7436-7440.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
5. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, et al. (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580.
6. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
7. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245.
8. Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, et al. (2005) Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65: 2465-2473.
9. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, et al. (2006) Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66: 6521-6529.
10. Bauer AJ, Cavalli LR, Rone JD, Francis GL, Burch HB, et al. (2002) Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis. Cancer Genet Cytogenet 135: 182-186.
11. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H, (1999) DNA copy number changes in thyroid carcinoma. Am J Pathol 154: 1539-1547.
12. Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, et al. (2000) Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Surgery 128: 888-893;discussion 893-884.
13. Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, et al. (2004) Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer 40: 355-364.
14. Richter H, Braselmann H, Hieber L, Thomas G, Bogdanova T, et al. (2004) Chromosomal imbalances in post-chernobyl thyroid tumors. Thyroid 14: 1061-1064.
15. Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, et al. (2007) Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep 18: 917-926.
16. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, et al. (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64: 3780-3789.
17. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, et al. (2002) Genome-wide appraisal of thyroid cancer progression. Am J Pathol 161: 1549-1556.
18. Unger K, Malisch E, Thomas G, Braselmann H, Walch A, et al. (2008) Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene 27: 4592-4602.
19. Finn S, Smyth P, O'Regan E, Cahill S, Toner M, et al. (2007) Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131: 65-73.
20. Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, et al. (2009) Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One 4: e7464.
21. Tuna M, Knuutila S, Mills GB, (2009) Uniparental disomy in cancer. Trends Mol Med 15: 120-128.
22. Makishima H, Maciejewski JP, (2011) Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res 17: 3913-3923.
23. Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, et al. (2010) Copy number and gene expression alterations in radiation-induced papillary thyroid carcinoma from chernobyl pediatric patients. Thyroid 20: 475-487.
24. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, et al. (2010) A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 90: 1285-1294.
25. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, et al. (2005) A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071-6079.
26. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81: 114-126.
27. Tiu RV, Gondek LP, O'Keefe CL, Huh J, Sekeres MA, et al. (2009) New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 27: 5219-5226.
28. O'Keefe C, McDevitt MA, Maciejewski JP, (2010) Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 115: 2731-2739.
29. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, et al. (2008) 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68: 10349-10357.
30. Higgins ME, Claremont M, Major JE, Sander C, Lash AE, (2007) CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 35: D721-726.
31. Kumagai A, Namba H, Akanov Z, Saenko VA, Meirmanov S, et al. (2007) Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 54: 399-405.
32. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, et al. (2007) Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27: 3645-3649.
33. Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, et al. (2009) Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J 56: 407-414.
34. Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, et al. (2007) Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57: 12-20.
35. Feldt-Rasmussen U, (2001) Iodine and Cancer. Thyroid 11: 4.
36. Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, et al. (2008) Morphologic characteristics of Chernobyl-related childhood papillary thyroid carcinomas are independent of radiation exposure but vary with iodine intake. Thyroid 18: 847-852.
37. Guan H, Ji M, Bao R, Yu H, Wang Y, et al. (2009) Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94: 1612-1617.
38. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, et al. (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56: 89-97.
39. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, et al. (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75: 1131-1135.
40. Hsu FF, Lin TY, Chen JY, Shieh SY, (2010) p53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control. Oncogene 29: 2864-2876.
41. Anania MC, Sensi M, Radaelli E, Miranda C, Vizioli MG, et al. (2011) TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. Oncogene 30: 3011-3023.
42. Viglietto G, Amodio N, Malanga D, Scrima M, De Marco C, (2011) Contribution of PKB/AKT signaling to thyroid cancer. Frontiers in Bioscience 16: 1461-1487.
43. Xing M, (2010) Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20: 697-706.
44. Zuo H, Gandhi M, Edreira MM, Hochbaum D, Nimgaonkar VL, et al. (2010) Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Research 70: 1389-1397.
45. Nellore A, Paziana K, Ma C, Tsygankova OM, Wang Y, et al. (2009) Loss of Rap1GAP in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 94: 1026-1032.
46. Siironen P, Ristimaki A, Narko K, Nordling S, Louhimo J, et al. (2006) VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr Relat Cancer 13: 465-473.
47. Hung CJ, Ginzinger DG, Zarnegar R, Kanauchi H, Wong MG, et al. (2003) Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88: 3694-3699.